LYNX LICENSES RESTENOSIS COMPOUND TO WELLCOME FOR UP TO $30 MIL.
Executive Summary
LYNX LICENSES RESTENOSIS COMPOUND TO WELLCOME FOR UP TO $30 MIL. in an agreement signed Aug. 4. The agreement covers development and marketing rights for a synthetic antisense oligonucleotide developed by Hayward, Calif.-based Lynx Therapeutics for the treatment of restenosis. The oligonucleotide is "about to enter" human clinical trials. Lynx developed the oligonucleotide in collaboration with Thomas Jefferson University.